Skip to main content

Table 3 Percentage and number of persistent vs. non-persistent patients per quartile of predicted scores based on baseline MSQoL-54 Physical and MSSES Control scores

From: Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)

Quartile Percentage non-persistent patients Percentage persistent patients N total
4 23.40 (n = 11) 76.60 (n = 36) 47
3 25.00 (n = 12) 75.00 (n = 36) 48
2 46.81 (n = 22) 53.19 (n = 25) 47
1 53.19 (n = 25) 46.81 (n = 22) 47
Total 37.04 (n = 70) 62.96 (n = 119) 189
  1. MSQoL-54 Multiple Sclerosis Quality of Life-54, MSSES Multiple Sclerosis Self-Efficacy Scale; Χ 2 = 13.91, p = 0.0030